{"ticker": {"uuid": "ecdcbe38-e1c5-4ccf-ad67-0ffa8ce94261", "symbol": "RXST", "name": "Rxsight Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Medical Devices"}, "articles": [{"title": "BlackRock Portfolio Management (RXST) discloses 7.2% beneficial stake in RxSight", "summary": "BlackRock Portfolio Management LLC has disclosed a 7.2% beneficial ownership stake in RxSight, Inc. (RXST), holding 2,982,816 shares as of June 30, 2026. The firm maintains sole voting power over 2,618,543 shares and sole dispositive power over all 2,982,816 shares, with no share", "url": "https://www.stocktitan.net/sec-filings/RXST/schedule-13g-rx-sight-inc-passive-investment-disclosure-5-3dbdf898f21e.html", "source_name": "Stock Titan", "published_at": "2026-07-17T15:10:39", "published_display": "17 Jul 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTIG Maintains RxSight(RXST.US) With Hold Rating, Announces Target Price $5.25", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxORmYyalRCZkh3RUxJUFNIWjZTTG8wek9rWHdLaXBDZTJjRXRSZk82QkJWZllBQ09JYjRHa1k5dDlHS3ZDNi1MT1FDVXRrZHNfM0RheExkeWFTenhIdTd0YjdTQmdvcER1dUp6akd0MzJ4VURHcUE2R0FoaXZKdGtRMXJwcTFKT3hfZnR6ejl0M2RVdEhpcGhjTUk1MVppOUk0VjU4U2ktR2FGOXZmUFBaMw?oc=5", "source_name": "Moomoo", "published_at": "2026-07-17T12:54:28+00:00", "published_display": "17 Jul 2026 12:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Kazia Therapeutics (KZIA) and Crescent Biopharma (CBIO)", "summary": "Healthcare companies RxSight (RXST), Kazia Therapeutics (KZIA), and Crescent Biopharma (CBIO) have recently received analyst coverage. BTIG analysts offered ratings for RxSight and Kazia Therapeutics, while H.C. Wainwright provided an update for Crescent Biopharma. The article de", "url": "https://www.theglobeandmail.com/investing/markets/stocks/KZIA-Q/pressreleases/3332990/analysts-offer-insights-on-healthcare-companies-rxsight-rxst-kazia-therapeutics-kzia-and-crescent-biopharma-cbio/", "source_name": "The Globe and Mail", "published_at": "2026-07-17T11:42:17", "published_display": "17 Jul 2026 11:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight (RXST) Surges 6.1%: Is This an Indication of Further Gains?", "summary": "RxSight (RXST) shares increased by 6.1% to $5.57, driven by high trading volume and investor optimism regarding an upcoming leadership transition. Aziz Mottiwala is set to become the new President and CEO on July 20, 2026. Despite a projected quarterly loss of $0.21 per share and", "url": "https://finance.yahoo.com/markets/stocks/articles/rxsight-rxst-surges-6-1-075000836.html", "source_name": "Market source", "published_at": "2026-07-17T08:11:49", "published_display": "17 Jul 2026 08:11", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alcon (SWX:ALC) After The RxSight Deal Is The Growth Story Already Priced In", "summary": "Alcon (SWX:ALC) has gained attention after a collaboration with RxSight for adjustable presbyopia-correcting intraocular lenses, leading to recent share price momentum. However, despite a \"25.7% Undervalued\" narrative targeting a fair value of CHF76.62 due to new product launches", "url": "https://simplywall.st/stocks/ch/healthcare/vtx-alc/alcon-shares/news/alcon-swxalc-after-the-rxsight-deal-is-the-growth-story-alre/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-16T19:41:26", "published_display": "16 Jul 2026 19:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight names Aziz Mottiwala as new CEO effective July 20", "summary": "RxSight, Inc. has announced the appointment of Aziz Mottiwala as its new President and Chief Executive Officer, effective July 20. Mottiwala succeeds Ron Kurtz, M.D., who will transition to Chief Medical Officer. This leadership change comes as RxSight's stock has faced significa", "url": "https://www.investing.com/news/company-news/rxsight-names-aziz-mottiwala-as-new-ceo-effective-july-20-93CH-4794238", "source_name": "Investing.com", "published_at": "2026-07-16T11:42:17", "published_display": "16 Jul 2026 11:42", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight Tags Aziz Mottiwala as President and CEO, Ron Kurtz, MD, as CMO", "summary": "RxSight, Inc. has announced a leadership transition, appointing Aziz Mottiwala as president and CEO, effective July 20, 2026. Current CEO Ron Kurtz, MD, will transition to chief medical officer and resign from the board of directors, with Mottiwala joining the board. This change ", "url": "https://www.visionmonday.com/eyecare/article/rxsight-tags-aziz-mottiwala-as-president-and-ceo-ron-kurtz-md-as-cmo/", "source_name": "VisionMonday.com", "published_at": "2026-07-16T04:40:54", "published_display": "16 Jul 2026 04:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight Appoints Aziz Mottiwala as CEO", "summary": "RxSight Inc. has appointed Aziz Mottiwala, former Tarsus Pharmaceuticals Chief Commercial Officer, as its new chief executive. Mottiwala replaces Ron Kurtz, who served as CEO for a decade and will now transition to chief medical officer. Following the announcement, shares in RxSi", "url": "https://www.ocbj.com/healthcare/rxsight-appoints-aziz-mottiwala-as-ceo/", "source_name": "Orange County Business Journal", "published_at": "2026-07-15T21:44:37", "published_display": "15 Jul 2026 21:44", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight Names Aziz Mottiwala as CEO", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/rxsight-names-aziz-mottiwala-ceo-204345728.html", "source_name": "MT Newswires", "published_at": "2026-07-15T20:43:45+00:00", "published_display": "15 Jul 2026 20:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/rxsight-announces-appointments-aziz-mottiwala-201500280.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T20:15:00+00:00", "published_display": "15 Jul 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight (NASDAQ: RXST) hires new CEO, sets $14M equity package", "summary": "RxSight, Inc. (NASDAQ: RXST) announced a leadership transition, appointing Aziz Mottiwala as President and CEO, effective July 20, 2026. Former CEO Ron Kurtz, M.D., will transition to Chief Medical Officer. Mottiwala's compensation package includes a $750,000 base salary, guarant", "url": "https://www.stocktitan.net/sec-filings/RXST/8-k-rx-sight-inc-reports-material-event-35e1633c0cd8.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:44:38", "published_display": "15 Jul 2026 20:44", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight names Aziz Mottiwala as new CEO effective July 20 By Investing.com", "summary": "RxSight, Inc. has announced Aziz Mottiwala as its new President and CEO, effective July 20, replacing Ron Kurtz, who will become Chief Medical Officer. This leadership change occurs as RxSight's stock has seen a significant decline, though InvestingPro analysis suggests it may be", "url": "https://ca.investing.com/news/stock-market-news/rxsight-names-aziz-mottiwala-as-new-ceo-effective-july-20-93CH-4736075", "source_name": "Investing.com Canada", "published_at": "2026-07-15T20:44:38", "published_display": "15 Jul 2026 20:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight CEO Ron Kurtz to Continue as Chief Medical Officer", "summary": "RxSight (NASDAQ: RXST) announced a leadership transition effective July 20, 2026, appointing Aziz Mottiwala as President and Chief Executive Officer. Ron Kurtz, M.D., the current CEO, will transition to Chief Medical Officer, focusing on technology and clinical development, and w", "url": "https://www.stocktitan.net/news/RXST/rx-sight-announces-appointments-of-aziz-mottiwala-as-chief-executive-f1ts43yybnya.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:44:37", "published_display": "15 Jul 2026 20:44", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight Announces Appointments of Aziz Mottiwala as Chief", "summary": "RxSight, Inc. has announced a leadership transition, appointing Aziz Mottiwala as President and Chief Executive Officer, effective July 20, 2026. He succeeds Ron Kurtz, M.D., who will continue as the Chief Medical Officer. The company highlighted Mottiwala's extensive commercial ", "url": "https://www.globenewswire.com/news-release/2026/07/15/3328121/0/en/RxSight-Announces-Appointments-of-Aziz-Mottiwala-as-Chief-Executive-Officer-and-Ron-Kurtz-M-D-as-Chief-Medical-Officer.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T20:44:37", "published_display": "15 Jul 2026 20:44", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer", "summary": "RxSight has announced significant leadership changes, appointing Aziz Mottiwala as the new Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer, effective immediately. Mr. Mottiwala previously served as Chief Commercial Officer, while Dr. Kurtz was a co-founder an", "url": "https://www.moomoo.com/news/post/73029546/press-release-rxsight-announces-appointments-of-aziz-mottiwala-as-chief?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-15T20:40:54", "published_display": "15 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Reflecting On Medical Devices & Supplies - Specialty Stocks\u2019 Q1 Earnings: Integer Holdings (NYSE:ITGR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUFd1SUpRcWlCdEFjU1YzNTZkdjBfRkwyY2lBYjh1ZXZlZTlyVlpWSWx1bExvckFrNHNhUEdVTGNFWUxaMkVDZUV2c2hPS1h2YVhNSHNsVzFYNUFrNHBnRVM1STRsa2Zmb0VXeEQ4UFRGNDBOWXZfWVU5VFUyQ3JZZm9KamZMWXVDSEtNMWwyVktpaEZfRjVNU1BYaWJ3NnpNUmRyMEpsSzBXdw?oc=5", "source_name": "Market source", "published_at": "2026-07-14T18:07:11+00:00", "published_display": "14 Jul 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Alcon & RxSight Collaborate to Develop Adjustable PCIOL Technology", "summary": "Alcon and RxSight have partnered to develop adjustable presbyopia-correcting intraocular lenses (PCIOLs) for cataract patients, combining Alcon's optical designs with RxSight's light-adjustable technology. This collaboration aims to allow surgeons to fine-tune visual outcomes pos", "url": "https://finance.yahoo.com/healthcare/articles/alcon-rxsight-collaborate-develop-adjustable-134000076.html", "source_name": "Market source", "published_at": "2026-07-13T22:44:38", "published_display": "13 Jul 2026 22:44", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alcon, RxSight announce collaboration to develop adjustable presbyopia-correcting IOLs", "summary": "Alcon and RxSight have announced a non-exclusive collaboration to develop adjustable presbyopia-correcting intraocular lenses (PCIOLs). This partnership aims to combine RxSight's post-operative light-adjustable technology with Alcon's PCIOL optical designs, allowing surgeons to f", "url": "https://www.ophthalmologytimes.com/view/alcon-rxsight-announce-collaboration-to-develop-adjustable-presbyopia-correcting-iols", "source_name": "Ophthalmology Times Europe", "published_at": "2026-07-11T14:11:12", "published_display": "11 Jul 2026 14:11", "sentiment": "positive", "sentiment_pct": 95, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 Outlook", "summary": "RxSight reported a 20% year-over-year decline in Q2 sales, excluding collaboration revenue, reaching approximately $27 million, with Light Adjustable Lens unit sales down 10%. Despite these near-term headwinds attributed to competitive launches and weaker consumer sentiment, the ", "url": "https://finance.yahoo.com/healthcare/articles/rxsight-q2-sales-sink-20-020156993.html", "source_name": "Market source", "published_at": "2026-07-11T01:41:22", "published_display": "11 Jul 2026 01:41", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight (RXST) Faces Investigation Over Board's Fiduciary Duties", "summary": "RxSight Inc (RXST), a medical device company, is under investigation by Glancy Prongay Wolke & Rotter LLP for potential breaches of fiduciary duties by its board of directors. This follows a significant decline in its Q2 2025 financial performance, attributed to challenges in sal", "url": "https://www.gurufocus.com/news/8954016/rxsight-rxst-faces-investigation-over-boards-fiduciary-duties", "source_name": "GuruFocus", "published_at": "2026-07-10T20:41:22", "published_display": "10 Jul 2026 20:41", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight: After Dropping To The Bottom, It's Time To Pick It Up (NASDAQ:RXST)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOV1lleHppYUdpRFpjRS1VV3EzenM2UVF1QkFmUzdEaUItZ2NfbFJ2NXhOT3dYNUFIa0V1TkpZLTI1VEZZVFRzY21PekgtLU80U1BjZFFRYWZxSlZ6YWpQTE1zQURGSjhJNkVTRWwxaUszdEwtWWFGLVlwNkxOZ1BPMDRYcUh5Sk95MXU4UkloOUNVTUVEWTctYl9mZTlYaVlLUVE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-10T18:20:39+00:00", "published_display": "10 Jul 2026 18:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glancy Prongay Wolke & Rotter LLP Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors", "summary": "Glancy Prongay Wolke & Rotter LLP has announced an investigation into RxSight, Inc. (RXST) concerning potential breaches of fiduciary duties by its board of directors. This comes after RxSight reported significant declines in its preliminary Q2 2025 financial results, including L", "url": "https://aijourn.com/glancy-prongay-wolke-rotter-llp-announces-investigation-of-rxsight-inc-rxst-on-behalf-of-investors/", "source_name": "The AI Journal", "published_at": "2026-07-10T17:41:24", "published_display": "10 Jul 2026 17:41", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Alcon (SWX:ALC) Cheap Following Its RxSight Collaboration And Premium P E?", "summary": "Alcon (SWX:ALC) recently announced a collaboration with RxSight to co-develop intraocular lenses, putting its cataract technology in focus, yet its stock is down 11% over 90 days and 21% annually. While a \"most popular narrative\" suggests the stock is 29.5% undervalued with a fai", "url": "https://simplywall.st/stocks/ch/healthcare/vtx-alc/alcon-shares/news/is-alcon-swxalc-cheap-following-its-rxsight-collaboration-an", "source_name": "Simply Wall Street", "published_at": "2026-07-09T01:41:06", "published_display": "09 Jul 2026 01:41", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Law Offices of Howard G. Smith Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors", "summary": "The Law Offices of Howard G. Smith announced an investigation into potential breaches of fiduciary duties by the board of directors of RxSight, Inc. (RXST). This follows RxSight's preliminary Q2 2025 financial results, which showed significant declines in sales and revenue, leadi", "url": "https://markets.financialcontent.com/stocks/article/bizwire-2026-7-8-law-offices-of-howard-g-smith-announces-investigation-of-rxsight-inc-rxst-on-behalf-of-investors", "source_name": "FinancialContent", "published_at": "2026-07-08T16:00:00", "published_display": "08 Jul 2026 16:00", "sentiment": "negative", "sentiment_pct": 27, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight: Alcon Deal Reshapes The Long-Term Growth Story (NASDAQ:RXST)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOZzZ3aDdhSk5ab0U1UThsMTM3YTNldWVMOHVBOUxBTFRzN2dTOWY1ZVpGbzE3amNSVWVETDlYYzNDZU5Vd3BjTVItT2tCUXFFR2NPRHVIdVktUUplNDhtQlVodFp1b3J3TlpPVkdCWHFnQlQ2YUl5Q0dsR2g0MFJEdzloZFJrc1BadDltbnJwbVFsWkFGcFBYR3g3TQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of RxSight, Inc. \u2013 NASDAQ:RXST", "summary": "This article provides the \"Price to book forward\" financial metric for RxSight, Inc. (NASDAQ: RXST). It displays the period, value, change, and percentage change for this specific financial indicator. The content is presented within the context of TradingView's platform, indicati", "url": "https://www.tradingview.com/symbols/NASDAQ-RXST/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T05:11:36", "published_display": "08 Jul 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight, Inc. Reports Preliminary Financial Results for the Second Quarter of 2026", "summary": "RxSight, Inc. has released preliminary financial results for Q2 2026, projecting total revenue between $32 million and $34 million, including revenue from a strategic collaboration with Alcon. Despite commercial headwinds, the company is accelerating investments in its sales forc", "url": "https://www.visionmonday.com/eyecare/article/rxsight-inc-reports-preliminary-financial-results-for-the-second-quarter-of-2026", "source_name": "VisionMonday.com", "published_at": "2026-07-08T04:39:24", "published_display": "08 Jul 2026 04:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alcon, RxSight partner on adjustable lens technology", "summary": "Alcon and RxSight Inc. have announced a non-exclusive collaboration to develop adjustable presbyopia-correcting intraocular lenses for cataract surgery patients. RxSight will receive an upfront payment of $60 million and potentially an additional $140 million based on development", "url": "https://www.investing.com/news/company-news/alcon-rxsight-partner-on-adjustable-lens-technology-93CH-4777436", "source_name": "Investing.com", "published_at": "2026-07-07T20:46:58", "published_display": "07 Jul 2026 20:46", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Law Offices of Frank R. Cruz Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors", "summary": "The Law Offices of Frank R. Cruz has initiated an investigation into potential breaches of fiduciary duty by the board of directors of RxSight, Inc. (RXST) following significant declines in the company's Q2 2025 financial results and a lowered full-year guidance. This investigati", "url": "https://www.businesswire.com/news/home/20260707716792/en/The-Law-Offices-of-Frank-R.-Cruz-Announces-Investigation-of-RxSight-Inc.-RXST-on-Behalf-of-Investors", "source_name": "Business Wire", "published_at": "2026-07-07T19:11:43", "published_display": "07 Jul 2026 19:11", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA cuts RxSight stock price target on weak Q2 sales, guidance", "summary": "BofA Securities has lowered its price target for RxSight Inc. (RXST) to $6.50 from $8.00, maintaining an Underperform rating, due to weak preliminary second-quarter sales and a reduced 2026 guidance. The company reported preliminary Q2 sales of $27 million, below estimates, and l", "url": "https://www.investing.com/news/analyst-ratings/bofa-cuts-rxsight-stock-price-target-on-weak-q2-sales-guidance-93CH-4779819", "source_name": "Investing.com", "published_at": "2026-07-07T17:11:43", "published_display": "07 Jul 2026 17:11", "sentiment": "negative", "sentiment_pct": 29, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight stock tumbles on reduced 2026 sales guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNT2xKWmN0UXJwaEdQRWlwRmRSSjM2RGVLMi1pRnBTQWoyYzNEa1Zhd2R3UVkxb0Fkc2ppWVh2bzAwR2M3WWxzeUFGU2Z4bEN3eGgtNURJTkdOemNoTGV1R2FDNVpQN1RSX1FXaDBkZDNzc1lMcUNsWVNUVlJYTi1WRVR2TmJZdHBVdG9jQTNHVkdZRU9zWUo3UDVuYlB0ck5tTW1FYzBULXpHVHBJYVJJOXhOeVM?oc=5", "source_name": "Investing.com", "published_at": "2026-07-07T15:35:28+00:00", "published_display": "07 Jul 2026 15:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight Inc. (RXST) PT Lowered to $6.50 at BofA Securities", "summary": "BofA Securities analyst Craig Bijou has lowered the price target for RxSight Inc. (NASDAQ: RXST) to $6.50 from $8.00. The analyst maintained their rating on the stock. The article is premium content, requiring a subscription to read further details.", "url": "https://www.streetinsider.com/Analyst+Comments/RxSight+Inc.+%28RXST%29+PT+Lowered+to+%246.50+at+BofA+Securities/26740827.html", "source_name": "StreetInsider", "published_at": "2026-07-07T12:24:00", "published_display": "07 Jul 2026 12:24", "sentiment": "negative", "sentiment_pct": 31, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alcon spends up to $200m to co-develop customisable cataract lenses with RxSight", "summary": "Alcon and RxSight have partnered to co-develop presbyopia-correcting intraocular lenses (PCIOLs) for cataract patients, with Alcon investing up to $200 million. This collaboration aims to combine RxSight's light-adjustable technology with Alcon's optical designs to create customi", "url": "https://finance.yahoo.com/healthcare/articles/alcon-spends-200m-co-develop-110934560.html", "source_name": "Market source", "published_at": "2026-07-07T11:11:43", "published_display": "07 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs", "summary": "Alcon and RxSight have announced a non-exclusive collaboration to develop adjustable presbyopia-correcting intraocular lenses (PCIOLs). This partnership aims to combine RxSight's light-adjustable technology with Alcon's PCIOL optical designs to allow surgeons to fine-tune visual ", "url": "https://uk.finance.yahoo.com/news/alcon-rxsight-announce-collaboration-develop-201500145.html", "source_name": "Market source", "published_at": "2026-07-07T08:11:36", "published_display": "07 Jul 2026 08:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alcon, RxSight Launch Collaboration to Develop Adjustable Presbyopia-Correcting Lenses", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alcon-rxsight-launch-collaboration-develop-204751320.html", "source_name": "MT Newswires", "published_at": "2026-07-06T20:47:51+00:00", "published_display": "06 Jul 2026 20:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/rxsight-inc-announces-preliminary-second-201500015.html", "source_name": "GlobeNewswire", "published_at": "2026-07-06T20:15:00+00:00", "published_display": "06 Jul 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alcon and RxSight team up on adjustable lenses after cataract surgery", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNZUU3TXFDUDE5d05YMjlqT3AtZmJGVFBFR3FVV1BLNi11b2RPLU5NTUpnaWJLa3RqZUFDeFAyNnJtQ3JINFpmSlo0Zk5aQzlfODFtNVBMNUd1V0tqa1hjekJpVmJjRmJaSkl3RE1vRXhfcXRmOEU0azlWQWRiOHI2cGRXOWxFc1FZV3Y2LXBPaURzNGdVMlM0M2VXSkpOS2tia1k3Q2lyTnFZcVliSTViVDlCVlBPZXRCbjk4QUhKQk8?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alcon\u2013RxSight (NASDAQ: RXST) deal adds $60M upfront plus milestones, royalties", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQLS1xLVRfeUZXX3dqLVlrSG01ZUoxVWpVdHRmTXkwVXRpWU9NMHN3d19xa0R1MlVRaUVoTmhEY0FpdEl0VC1CZk5RRGxES3dWNElEcTRZWXE1bmxWaWoyNTNCOGp6UjdGN0I5dVdaTmZzYWxtbC1LNVBjeHVQNUUzRlV5aEFybDdvYkNDN05pQnZ1d3ZaM0FBNUgxcnkxTnBOQVJF?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight sees Q2 sales of $27M as Alcon deal adds revenue", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPTHlVZGhxOHNVdkU2cFZab3B6bE1xRVZYWVdKbklMQUZVWFV6SWF6V25TNEdMNERlNXBhOEMyNTRGYy1nT3lpcEswUUNPbEZiYWEtc0piZHVqSGp1aTRObWtHQXRJemRUMlpxaDJSclBnM1RKVDFjbGlNQTBRMkVyWmZkNFVHajhsY19qUV9TTEozblBwblFmM1h4QnotRDVDYnRCc2dtZ1Q2SDlJYXJTd2FvS3FfYXpjWGJfNnliaw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight (NASDAQ: RXST) cuts 2026 sales outlook but lifts margin view", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPRzdvWWx3SnVPRU14aUJ0UmxQTEN2S2xwREhDdHlhcFJjNHFHNHlWSFRXaS1UNDRWa3o4a0ZVSEhjekR3M2t6VWlHMW93WTZTMkc4dVJlSldJWFJIaDhHblJYVjlUWWFuT3ZYYlViV3pwVGFQb0N1aGpOVzh6TXZackxxRElzMGZwNnktaG9OeUpRUDN3VW9TTENNODVHSURUNUFJ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTWR3bzJReVB0UTNleWx6WDlmRW1rYmpLdkptZHdadzVERk1hTzdEV0M1Z2tuRUx2cldOT2d3WlVDank5Y01EWWFfWXdWNkJFdkNFcnhjMjdCQ1Y2aFBVbndiNXVBY0F5dDRpU2Fla25fVWRTUlNROXFwYXNXT2czUm5Nbl9QUFhFTEhHd1ZKTzJUSzhJWjN6QnNNUEVBTVEyR0l6YkZacUVsdw?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q1 Earnings Outperformers: Artivion (NYSE:AORT) And The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQWlEweko5d2hyZUFhUjRsYU1QcElacmR0UktDcFZGUmFXSHpGN05OLV9tYS1VRTlfTHpGRXEzNi12cXZlcTJYVDhZRTZnWG1DUEVFT3hxMG5RcUpORUsyQWN3VVY0eENoZnFMYkdLOXk1Y2d5SFluWDBZU2ZsUl90cHZWY2pKQXZwS212WkcxejJjQ3hlYmtqMFRhWm1neHVYRDZvUzFtVmM4dXVY?oc=5", "source_name": "Market source", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rxsight-inc-present-stifel-2026-201000843.html", "source_name": "GlobeNewswire", "published_at": "2026-05-19T20:10:00+00:00", "published_display": "19 May 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxONzhoNFFST0l5S0xFZGFmMDR4YjJ6VDhQTnNjVkcxS2RJUUxTUjlZZGJqYV9PcnlheGVGYU9URzFua0JPa19IVmtXVDNkdDVpQUNQdC1wd2wyWTJDTG11eExRcGNDMVBrbmFlYXpqMXlQSXRab2JVR0IzTU9sRzRHNzdzQzM0UlRIVkctR3MwZkYtREtIeU96SGE4SDJ5ZEgyeEFQVGp5OA?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxObXd3RVVzUHNTYUtibnhTZXRCQ1g3WEVGd2ducVhmYURZLVN0OTd1TEpPV2c2VGJHRG9TZU5NaXhNbjJDZTdnUDZqSzJ4TVoyRXJIYkwwT1V3c2FUdHdjbWxwZzNIazFmR25XSzFJcThqaFdia3RycUZfMW54WVR2TTVSSlpNVXVRdFJ6blZGV0VHZ0lIcHk1QUZhTDlqakV0dHI3N1JQeXFCVUR6X01Zek5weFo3dl9rRjRsRGJBbURJVnJFeWtGVE5BSHJCOURRVWI4bldSU0ZzOHRUUk9uOGpwUW9keFA2UVI2UEp3?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Diversified Stocks Q1 Results: Benchmarking Stryker (NYSE:SYK)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNb1NaVXV6UW42emtDUzh5ckhKVjc2X29fSlFRRDVIVnRLWXpoWEYxUnVKNGZuLVN6ZWhxVno1SGluMEdLcmNrOGN1ZjlsWFpVRWxYbW9aYy01VFFpVzlncWtBYzF3YkJfNzhwTi1BcWlpVF9pUTU4QnNGWkJSV3YwRXVCUzk2Z2NUMWFjVkJOV2hSbFRrRnIxSWxNUGRoQmhQeDVBRjhYSnhvMDJqUThjYjBHRjhTRTBDdDZJd1k3LU5DTjU2cUx6TXFNdHhVS1FfdlFmaWZLNk41cFk?oc=5", "source_name": "StockStory", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "How The RxSight (RXST) Narrative Is Shifting After 2026 Guidance And Target Resets", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPTGY2WVJ5RE1zSUxmejBmOTlvTUQ4UlBmY3ZuSzBLcGF0akVFMEs2WllRQWV6RWFJWnVMdnl6UXlId2VJbW1INWlRRDBQa3RUb1RVZi1md1YtNmxKNUNvc0swbW5rekZvUVQ3LVZIU0FFTlBWeVFvZ1FZS25Qd0hHNU5OM1ZJeWtwNWRSMks1T0JGdmlhWU1teWk1eFdGejgwMHg4?oc=5", "source_name": "Market source", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors can watch RxSight's Bank of America fireside chat May 13", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOaXc3MHVJcExubmdmR1c1WmwtOXhmM1hGcVI2QzROUWpIdEJJWjh2aHFGY21qb3d4V1Z3b3pYa0NWb002UTh1STQtNHFqWDNUbU1ndlFwOVpoTWlod0Y5dm95QV91Y3pOVWxuTXpxcUt5aVNJLUdlQXppX0pRZmdDOHdGSWI4VlBEVTRUdHhEMGU5OUkxamxFdjlscC1EWEpibXNZcWoyQUtiZG51WGF1NUZn?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcDFMNmtOVk5PVFM1YzMyVWhyS3dwY0dMVE5BUng5U1JoOFRQMXNFRGxTMmlBRUV0bENRSWFXTDFZOXBQQkNZT0FOWDdISjRCcU9pRV9aNHBwUVBuZkVEV3g1dklVY19KOE9iWUNpNUtMS2NuOEcxMlQtNU8ydURybEdkNVoxZThWLTBIeVhid2NjQ0FWWTUzb2dxcmlMQThFQmZ4bldzRjcwUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks\u2019 Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOdkl6Ym5HSGVhZUw3TzNlNVFPSjdDQk5NMTVSRW1xVnh3RE5RNU9veVR0TDEtcVdxV3BYelI0bWxCYXgwWmhZQ3ZONUVRdlhjX0ZiMklRVDJQRXN0LXcyVWVnb0E2WTdiRERtZk1pNGpmVHhWbHl5eHJuNnBtTDVPMUluTmRsQUVqYjNlSl8zR3djclh0X2ZIc1gzTlhPanR6ZTJ6R1FB?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "How The Story Is Shifting For RxSight (RXST) On Guidance Leadership And Valuation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPZlVIX00yd3FXS2pHQUtHb1F4dDQ3Yk94ZlYyOWtYWW51ckdqMVBqVmp1bEF6a3Ytb1YzREdlQ3VKZnNpV1BBYzVERHJFS19BR0VsYWo2Z015THYwWDBDTkNDbHQ5MzlKQlpTcFBVOV9KWU42YXhDTHEwWnhkTmk0VHFndVhpczFsYXNWNlNFaXM0N01JaElhWnUxRXcwRjVIVXNn?oc=5", "source_name": "Market source", "published_at": "2026-04-04T07:00:00+00:00", "published_display": "04 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaTgxS3dlMlZ5dDZ3dFlGdG9yRWFubkVqMk9yOTN6OEtyemljTWJGYUcxb2pmd2FTNTFKMlhIVGxrdlJsOG5iY1VQaXE4ZmYycTVpRkE0aEJ3QlB5bC10ZXN2dTFYNy0wRWdrNURVUlo5dEMzQklxQ0kwQTRkOXE0UDdTMkRGRWxoQ1ZQeG4tOXNONlR2SkxfZW5ST1B6N3BBeFZZQ3N1UFE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: CooperCompanies (NASDAQ:COO) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOellVLTAtRXF1dTFacmVLUmptUVpDSkxGX0MtY2hCY2l3ajU4M25SMG95OHdlc1RHN1dmaHZZMF9uQ0o3R1FBa0NzQUtZMjIzMjU1bmttbGZsZUplQkd5Vmd2NEJoQ0NnbVhmVXppdWhiQkdpcGpQVFJVSHRBXy1pbnFJbXI0R2w3MmlvMEdCY2dGYVE4cWY2MENmeEp1ME9mZEFqSDVtdThTMk9kbUhIdXMtR0k?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Integer Holdings (NYSE:ITGR) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxQZXhDWktWZlhhSHlxNVZrNWllaDhhWlNXZmhKYlQ4ODRJMHozNTR2TVVKSWVrQV94bzNNU0hfVW5qODRlWW01anFmTG5SYmZoUlJpU09UbkpSemxVbHRGb1F1MGVvZFdqSEVBcUZ5Ti1ZVHlzY3pZYTdCS21RcDJPTnppdWRKVlZjd2ZUeA?oc=5", "source_name": "Market source", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPeVpVN2I3X3lJNXd3TXJmRWV4X0RvRDdYR3l5a1k1SjMxUlhsWHdrUUNuZ1JIaUg4czdhZlA2VDVIallROFFuNmZXcnNzS1d3Vm0wS0tLMmlFVWdkUThsRDZYdTdZV3k3WkRjaUZSMUQ3dkRKYm5ZOVBjMVVBdTRjYQ?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNMzBPcXU1cnZKekZnaGlNVk05ZWFTWThNOS0tTlpvQjdaLVZIWlVXUk50NnVoQ0pPWWJpZUpWcVJyVDJMd2RJREVDbEEzTlU5UGhBbWtxWVEyVkdaMTVuNXZpaWFMNTZUQ2d0OW9Rc29kalJRY21naWlHZDBLS3RuZV9wdTdIUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "RxSight, Inc. Common Stock (RXST) Stock Price Today: $5.25", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTFBOYnBmNE1CQzFhRmdpNFZYMGN0T3dQWDB0a3VBMm1uNFhmLS04c25OcHotc2x5N1N2cllPa0FIUkhMRzZSN3BTbHJiN2hwN0tPYUVYejBxZw?oc=5", "source_name": "Gotrade", "published_at": "2026-01-13T02:40:24+00:00", "published_display": "13 Jan 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Hopeful That RxSight (NASDAQ:RXST) Will Use Its Cash Wisely", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-10T08:00:00+00:00", "published_display": "10 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight, Inc. Reports Third Quarter 2024 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOOFlkRTlwY3lDX3lyUmVKc2lwaks4aEdvN0lqVnl6d2gtSVJpa3JwX2JpYUMtbjFmREtoZERZOWdfZW5oRGgxV25KOEM3RjNZTlVab2JoRWJ5NS1GNFpIQVRZLWhlUVNmOHJyY0d4SjF3WUdHSW9lMzZjU0tXTGx3RzdEZm1zSzI1ZHZuNDVBZERXQk9FcDl5TWFHQ2N0czZBTzdZMVBlRzBBcXBrNTMxWXF5N2JZc1VTRDJQQXFDV0lSY1kxUVE?oc=5", "source_name": "GlobeNewswire", "published_at": "2024-11-07T08:00:00+00:00", "published_display": "07 Nov 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight (RXST) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE9uaTA0bTRkbVU5dGNmTUltMlNkZE9jZlBGMFVfRmYzMkpmbHJxb0xsZjE3aXJYOGlmUDdBdzh4X0pnRFRIeW8zTGh3S29jWGpCeFlibG9LcHBnQkFkQm9kMm9VWUVyUQ?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T14:53:49+00:00", "published_display": "11 May 2024 14:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "BlackRock Portfolio Management (RXST) discloses 7.2% beneficial stake in RxSight", "summary": "BlackRock Portfolio Management LLC has disclosed a 7.2% beneficial ownership stake in RxSight, Inc. (RXST), holding 2,982,816 shares as of June 30, 2026. The firm maintains sole voting power over 2,618,543 shares and sole dispositive power over all 2,982,816 shares, with no share", "url": "https://www.stocktitan.net/sec-filings/RXST/schedule-13g-rx-sight-inc-passive-investment-disclosure-5-3dbdf898f21e.html", "source_name": "Stock Titan", "published_at": "2026-07-17T15:10:39", "published_display": "17 Jul 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTIG Maintains RxSight(RXST.US) With Hold Rating, Announces Target Price $5.25", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxORmYyalRCZkh3RUxJUFNIWjZTTG8wek9rWHdLaXBDZTJjRXRSZk82QkJWZllBQ09JYjRHa1k5dDlHS3ZDNi1MT1FDVXRrZHNfM0RheExkeWFTenhIdTd0YjdTQmdvcER1dUp6akd0MzJ4VURHcUE2R0FoaXZKdGtRMXJwcTFKT3hfZnR6ejl0M2RVdEhpcGhjTUk1MVppOUk0VjU4U2ktR2FGOXZmUFBaMw?oc=5", "source_name": "Moomoo", "published_at": "2026-07-17T12:54:28+00:00", "published_display": "17 Jul 2026 12:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Kazia Therapeutics (KZIA) and Crescent Biopharma (CBIO)", "summary": "Healthcare companies RxSight (RXST), Kazia Therapeutics (KZIA), and Crescent Biopharma (CBIO) have recently received analyst coverage. BTIG analysts offered ratings for RxSight and Kazia Therapeutics, while H.C. Wainwright provided an update for Crescent Biopharma. The article de", "url": "https://www.theglobeandmail.com/investing/markets/stocks/KZIA-Q/pressreleases/3332990/analysts-offer-insights-on-healthcare-companies-rxsight-rxst-kazia-therapeutics-kzia-and-crescent-biopharma-cbio/", "source_name": "The Globe and Mail", "published_at": "2026-07-17T11:42:17", "published_display": "17 Jul 2026 11:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight (RXST) Surges 6.1%: Is This an Indication of Further Gains?", "summary": "RxSight (RXST) shares increased by 6.1% to $5.57, driven by high trading volume and investor optimism regarding an upcoming leadership transition. Aziz Mottiwala is set to become the new President and CEO on July 20, 2026. Despite a projected quarterly loss of $0.21 per share and", "url": "https://finance.yahoo.com/markets/stocks/articles/rxsight-rxst-surges-6-1-075000836.html", "source_name": "Market source", "published_at": "2026-07-17T08:11:49", "published_display": "17 Jul 2026 08:11", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alcon (SWX:ALC) After The RxSight Deal Is The Growth Story Already Priced In", "summary": "Alcon (SWX:ALC) has gained attention after a collaboration with RxSight for adjustable presbyopia-correcting intraocular lenses, leading to recent share price momentum. However, despite a \"25.7% Undervalued\" narrative targeting a fair value of CHF76.62 due to new product launches", "url": "https://simplywall.st/stocks/ch/healthcare/vtx-alc/alcon-shares/news/alcon-swxalc-after-the-rxsight-deal-is-the-growth-story-alre/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-16T19:41:26", "published_display": "16 Jul 2026 19:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight names Aziz Mottiwala as new CEO effective July 20", "summary": "RxSight, Inc. has announced the appointment of Aziz Mottiwala as its new President and Chief Executive Officer, effective July 20. Mottiwala succeeds Ron Kurtz, M.D., who will transition to Chief Medical Officer. This leadership change comes as RxSight's stock has faced significa", "url": "https://www.investing.com/news/company-news/rxsight-names-aziz-mottiwala-as-new-ceo-effective-july-20-93CH-4794238", "source_name": "Investing.com", "published_at": "2026-07-16T11:42:17", "published_display": "16 Jul 2026 11:42", "sentiment": "negative", "sentiment_pct": 33, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight Tags Aziz Mottiwala as President and CEO, Ron Kurtz, MD, as CMO", "summary": "RxSight, Inc. has announced a leadership transition, appointing Aziz Mottiwala as president and CEO, effective July 20, 2026. Current CEO Ron Kurtz, MD, will transition to chief medical officer and resign from the board of directors, with Mottiwala joining the board. This change ", "url": "https://www.visionmonday.com/eyecare/article/rxsight-tags-aziz-mottiwala-as-president-and-ceo-ron-kurtz-md-as-cmo/", "source_name": "VisionMonday.com", "published_at": "2026-07-16T04:40:54", "published_display": "16 Jul 2026 04:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight Appoints Aziz Mottiwala as CEO", "summary": "RxSight Inc. has appointed Aziz Mottiwala, former Tarsus Pharmaceuticals Chief Commercial Officer, as its new chief executive. Mottiwala replaces Ron Kurtz, who served as CEO for a decade and will now transition to chief medical officer. Following the announcement, shares in RxSi", "url": "https://www.ocbj.com/healthcare/rxsight-appoints-aziz-mottiwala-as-ceo/", "source_name": "Orange County Business Journal", "published_at": "2026-07-15T21:44:37", "published_display": "15 Jul 2026 21:44", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight Names Aziz Mottiwala as CEO", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/rxsight-names-aziz-mottiwala-ceo-204345728.html", "source_name": "MT Newswires", "published_at": "2026-07-15T20:43:45+00:00", "published_display": "15 Jul 2026 20:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/rxsight-announces-appointments-aziz-mottiwala-201500280.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T20:15:00+00:00", "published_display": "15 Jul 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight (NASDAQ: RXST) hires new CEO, sets $14M equity package", "summary": "RxSight, Inc. (NASDAQ: RXST) announced a leadership transition, appointing Aziz Mottiwala as President and CEO, effective July 20, 2026. Former CEO Ron Kurtz, M.D., will transition to Chief Medical Officer. Mottiwala's compensation package includes a $750,000 base salary, guarant", "url": "https://www.stocktitan.net/sec-filings/RXST/8-k-rx-sight-inc-reports-material-event-35e1633c0cd8.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:44:38", "published_display": "15 Jul 2026 20:44", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight names Aziz Mottiwala as new CEO effective July 20 By Investing.com", "summary": "RxSight, Inc. has announced Aziz Mottiwala as its new President and CEO, effective July 20, replacing Ron Kurtz, who will become Chief Medical Officer. This leadership change occurs as RxSight's stock has seen a significant decline, though InvestingPro analysis suggests it may be", "url": "https://ca.investing.com/news/stock-market-news/rxsight-names-aziz-mottiwala-as-new-ceo-effective-july-20-93CH-4736075", "source_name": "Investing.com Canada", "published_at": "2026-07-15T20:44:38", "published_display": "15 Jul 2026 20:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight CEO Ron Kurtz to Continue as Chief Medical Officer", "summary": "RxSight (NASDAQ: RXST) announced a leadership transition effective July 20, 2026, appointing Aziz Mottiwala as President and Chief Executive Officer. Ron Kurtz, M.D., the current CEO, will transition to Chief Medical Officer, focusing on technology and clinical development, and w", "url": "https://www.stocktitan.net/news/RXST/rx-sight-announces-appointments-of-aziz-mottiwala-as-chief-executive-f1ts43yybnya.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:44:37", "published_display": "15 Jul 2026 20:44", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight Announces Appointments of Aziz Mottiwala as Chief", "summary": "RxSight, Inc. has announced a leadership transition, appointing Aziz Mottiwala as President and Chief Executive Officer, effective July 20, 2026. He succeeds Ron Kurtz, M.D., who will continue as the Chief Medical Officer. The company highlighted Mottiwala's extensive commercial ", "url": "https://www.globenewswire.com/news-release/2026/07/15/3328121/0/en/RxSight-Announces-Appointments-of-Aziz-Mottiwala-as-Chief-Executive-Officer-and-Ron-Kurtz-M-D-as-Chief-Medical-Officer.html", "source_name": "GlobeNewswire", "published_at": "2026-07-15T20:44:37", "published_display": "15 Jul 2026 20:44", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer", "summary": "RxSight has announced significant leadership changes, appointing Aziz Mottiwala as the new Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer, effective immediately. Mr. Mottiwala previously served as Chief Commercial Officer, while Dr. Kurtz was a co-founder an", "url": "https://www.moomoo.com/news/post/73029546/press-release-rxsight-announces-appointments-of-aziz-mottiwala-as-chief?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-15T20:40:54", "published_display": "15 Jul 2026 20:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alcon & RxSight Collaborate to Develop Adjustable PCIOL Technology", "summary": "Alcon and RxSight have partnered to develop adjustable presbyopia-correcting intraocular lenses (PCIOLs) for cataract patients, combining Alcon's optical designs with RxSight's light-adjustable technology. This collaboration aims to allow surgeons to fine-tune visual outcomes pos", "url": "https://finance.yahoo.com/healthcare/articles/alcon-rxsight-collaborate-develop-adjustable-134000076.html", "source_name": "Market source", "published_at": "2026-07-13T22:44:38", "published_display": "13 Jul 2026 22:44", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alcon, RxSight announce collaboration to develop adjustable presbyopia-correcting IOLs", "summary": "Alcon and RxSight have announced a non-exclusive collaboration to develop adjustable presbyopia-correcting intraocular lenses (PCIOLs). This partnership aims to combine RxSight's post-operative light-adjustable technology with Alcon's PCIOL optical designs, allowing surgeons to f", "url": "https://www.ophthalmologytimes.com/view/alcon-rxsight-announce-collaboration-to-develop-adjustable-presbyopia-correcting-iols", "source_name": "Ophthalmology Times Europe", "published_at": "2026-07-11T14:11:12", "published_display": "11 Jul 2026 14:11", "sentiment": "positive", "sentiment_pct": 95, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 Outlook", "summary": "RxSight reported a 20% year-over-year decline in Q2 sales, excluding collaboration revenue, reaching approximately $27 million, with Light Adjustable Lens unit sales down 10%. Despite these near-term headwinds attributed to competitive launches and weaker consumer sentiment, the ", "url": "https://finance.yahoo.com/healthcare/articles/rxsight-q2-sales-sink-20-020156993.html", "source_name": "Market source", "published_at": "2026-07-11T01:41:22", "published_display": "11 Jul 2026 01:41", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight (RXST) Faces Investigation Over Board's Fiduciary Duties", "summary": "RxSight Inc (RXST), a medical device company, is under investigation by Glancy Prongay Wolke & Rotter LLP for potential breaches of fiduciary duties by its board of directors. This follows a significant decline in its Q2 2025 financial performance, attributed to challenges in sal", "url": "https://www.gurufocus.com/news/8954016/rxsight-rxst-faces-investigation-over-boards-fiduciary-duties", "source_name": "GuruFocus", "published_at": "2026-07-10T20:41:22", "published_display": "10 Jul 2026 20:41", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight: After Dropping To The Bottom, It's Time To Pick It Up (NASDAQ:RXST)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOV1lleHppYUdpRFpjRS1VV3EzenM2UVF1QkFmUzdEaUItZ2NfbFJ2NXhOT3dYNUFIa0V1TkpZLTI1VEZZVFRzY21PekgtLU80U1BjZFFRYWZxSlZ6YWpQTE1zQURGSjhJNkVTRWwxaUszdEwtWWFGLVlwNkxOZ1BPMDRYcUh5Sk95MXU4UkloOUNVTUVEWTctYl9mZTlYaVlLUVE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-10T18:20:39+00:00", "published_display": "10 Jul 2026 18:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Glancy Prongay Wolke & Rotter LLP Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors", "summary": "Glancy Prongay Wolke & Rotter LLP has announced an investigation into RxSight, Inc. (RXST) concerning potential breaches of fiduciary duties by its board of directors. This comes after RxSight reported significant declines in its preliminary Q2 2025 financial results, including L", "url": "https://aijourn.com/glancy-prongay-wolke-rotter-llp-announces-investigation-of-rxsight-inc-rxst-on-behalf-of-investors/", "source_name": "The AI Journal", "published_at": "2026-07-10T17:41:24", "published_display": "10 Jul 2026 17:41", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Alcon (SWX:ALC) Cheap Following Its RxSight Collaboration And Premium P E?", "summary": "Alcon (SWX:ALC) recently announced a collaboration with RxSight to co-develop intraocular lenses, putting its cataract technology in focus, yet its stock is down 11% over 90 days and 21% annually. While a \"most popular narrative\" suggests the stock is 29.5% undervalued with a fai", "url": "https://simplywall.st/stocks/ch/healthcare/vtx-alc/alcon-shares/news/is-alcon-swxalc-cheap-following-its-rxsight-collaboration-an", "source_name": "Simply Wall Street", "published_at": "2026-07-09T01:41:06", "published_display": "09 Jul 2026 01:41", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Law Offices of Howard G. Smith Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors", "summary": "The Law Offices of Howard G. Smith announced an investigation into potential breaches of fiduciary duties by the board of directors of RxSight, Inc. (RXST). This follows RxSight's preliminary Q2 2025 financial results, which showed significant declines in sales and revenue, leadi", "url": "https://markets.financialcontent.com/stocks/article/bizwire-2026-7-8-law-offices-of-howard-g-smith-announces-investigation-of-rxsight-inc-rxst-on-behalf-of-investors", "source_name": "FinancialContent", "published_at": "2026-07-08T16:00:00", "published_display": "08 Jul 2026 16:00", "sentiment": "negative", "sentiment_pct": 27, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight: Alcon Deal Reshapes The Long-Term Growth Story (NASDAQ:RXST)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxOZzZ3aDdhSk5ab0U1UThsMTM3YTNldWVMOHVBOUxBTFRzN2dTOWY1ZVpGbzE3amNSVWVETDlYYzNDZU5Vd3BjTVItT2tCUXFFR2NPRHVIdVktUUplNDhtQlVodFp1b3J3TlpPVkdCWHFnQlQ2YUl5Q0dsR2g0MFJEdzloZFJrc1BadDltbnJwbVFsWkFGcFBYR3g3TQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-08T07:00:00+00:00", "published_display": "08 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of RxSight, Inc. \u2013 NASDAQ:RXST", "summary": "This article provides the \"Price to book forward\" financial metric for RxSight, Inc. (NASDAQ: RXST). It displays the period, value, change, and percentage change for this specific financial indicator. The content is presented within the context of TradingView's platform, indicati", "url": "https://www.tradingview.com/symbols/NASDAQ-RXST/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T05:11:36", "published_display": "08 Jul 2026 05:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight, Inc. Reports Preliminary Financial Results for the Second Quarter of 2026", "summary": "RxSight, Inc. has released preliminary financial results for Q2 2026, projecting total revenue between $32 million and $34 million, including revenue from a strategic collaboration with Alcon. Despite commercial headwinds, the company is accelerating investments in its sales forc", "url": "https://www.visionmonday.com/eyecare/article/rxsight-inc-reports-preliminary-financial-results-for-the-second-quarter-of-2026", "source_name": "VisionMonday.com", "published_at": "2026-07-08T04:39:24", "published_display": "08 Jul 2026 04:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alcon, RxSight partner on adjustable lens technology", "summary": "Alcon and RxSight Inc. have announced a non-exclusive collaboration to develop adjustable presbyopia-correcting intraocular lenses for cataract surgery patients. RxSight will receive an upfront payment of $60 million and potentially an additional $140 million based on development", "url": "https://www.investing.com/news/company-news/alcon-rxsight-partner-on-adjustable-lens-technology-93CH-4777436", "source_name": "Investing.com", "published_at": "2026-07-07T20:46:58", "published_display": "07 Jul 2026 20:46", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Law Offices of Frank R. Cruz Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors", "summary": "The Law Offices of Frank R. Cruz has initiated an investigation into potential breaches of fiduciary duty by the board of directors of RxSight, Inc. (RXST) following significant declines in the company's Q2 2025 financial results and a lowered full-year guidance. This investigati", "url": "https://www.businesswire.com/news/home/20260707716792/en/The-Law-Offices-of-Frank-R.-Cruz-Announces-Investigation-of-RxSight-Inc.-RXST-on-Behalf-of-Investors", "source_name": "Business Wire", "published_at": "2026-07-07T19:11:43", "published_display": "07 Jul 2026 19:11", "sentiment": "negative", "sentiment_pct": 19, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA cuts RxSight stock price target on weak Q2 sales, guidance", "summary": "BofA Securities has lowered its price target for RxSight Inc. (RXST) to $6.50 from $8.00, maintaining an Underperform rating, due to weak preliminary second-quarter sales and a reduced 2026 guidance. The company reported preliminary Q2 sales of $27 million, below estimates, and l", "url": "https://www.investing.com/news/analyst-ratings/bofa-cuts-rxsight-stock-price-target-on-weak-q2-sales-guidance-93CH-4779819", "source_name": "Investing.com", "published_at": "2026-07-07T17:11:43", "published_display": "07 Jul 2026 17:11", "sentiment": "negative", "sentiment_pct": 29, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight stock tumbles on reduced 2026 sales guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNT2xKWmN0UXJwaEdQRWlwRmRSSjM2RGVLMi1pRnBTQWoyYzNEa1Zhd2R3UVkxb0Fkc2ppWVh2bzAwR2M3WWxzeUFGU2Z4bEN3eGgtNURJTkdOemNoTGV1R2FDNVpQN1RSX1FXaDBkZDNzc1lMcUNsWVNUVlJYTi1WRVR2TmJZdHBVdG9jQTNHVkdZRU9zWUo3UDVuYlB0ck5tTW1FYzBULXpHVHBJYVJJOXhOeVM?oc=5", "source_name": "Investing.com", "published_at": "2026-07-07T15:35:28+00:00", "published_display": "07 Jul 2026 15:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight Inc. (RXST) PT Lowered to $6.50 at BofA Securities", "summary": "BofA Securities analyst Craig Bijou has lowered the price target for RxSight Inc. (NASDAQ: RXST) to $6.50 from $8.00. The analyst maintained their rating on the stock. The article is premium content, requiring a subscription to read further details.", "url": "https://www.streetinsider.com/Analyst+Comments/RxSight+Inc.+%28RXST%29+PT+Lowered+to+%246.50+at+BofA+Securities/26740827.html", "source_name": "StreetInsider", "published_at": "2026-07-07T12:24:00", "published_display": "07 Jul 2026 12:24", "sentiment": "negative", "sentiment_pct": 31, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alcon spends up to $200m to co-develop customisable cataract lenses with RxSight", "summary": "Alcon and RxSight have partnered to co-develop presbyopia-correcting intraocular lenses (PCIOLs) for cataract patients, with Alcon investing up to $200 million. This collaboration aims to combine RxSight's light-adjustable technology with Alcon's optical designs to create customi", "url": "https://finance.yahoo.com/healthcare/articles/alcon-spends-200m-co-develop-110934560.html", "source_name": "Market source", "published_at": "2026-07-07T11:11:43", "published_display": "07 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs", "summary": "Alcon and RxSight have announced a non-exclusive collaboration to develop adjustable presbyopia-correcting intraocular lenses (PCIOLs). This partnership aims to combine RxSight's light-adjustable technology with Alcon's PCIOL optical designs to allow surgeons to fine-tune visual ", "url": "https://uk.finance.yahoo.com/news/alcon-rxsight-announce-collaboration-develop-201500145.html", "source_name": "Market source", "published_at": "2026-07-07T08:11:36", "published_display": "07 Jul 2026 08:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alcon, RxSight Launch Collaboration to Develop Adjustable Presbyopia-Correcting Lenses", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/alcon-rxsight-launch-collaboration-develop-204751320.html", "source_name": "MT Newswires", "published_at": "2026-07-06T20:47:51+00:00", "published_display": "06 Jul 2026 20:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/rxsight-inc-announces-preliminary-second-201500015.html", "source_name": "GlobeNewswire", "published_at": "2026-07-06T20:15:00+00:00", "published_display": "06 Jul 2026 20:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alcon and RxSight team up on adjustable lenses after cataract surgery", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNZUU3TXFDUDE5d05YMjlqT3AtZmJGVFBFR3FVV1BLNi11b2RPLU5NTUpnaWJLa3RqZUFDeFAyNnJtQ3JINFpmSlo0Zk5aQzlfODFtNVBMNUd1V0tqa1hjekJpVmJjRmJaSkl3RE1vRXhfcXRmOEU0azlWQWRiOHI2cGRXOWxFc1FZV3Y2LXBPaURzNGdVMlM0M2VXSkpOS2tia1k3Q2lyTnFZcVliSTViVDlCVlBPZXRCbjk4QUhKQk8?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alcon\u2013RxSight (NASDAQ: RXST) deal adds $60M upfront plus milestones, royalties", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQLS1xLVRfeUZXX3dqLVlrSG01ZUoxVWpVdHRmTXkwVXRpWU9NMHN3d19xa0R1MlVRaUVoTmhEY0FpdEl0VC1CZk5RRGxES3dWNElEcTRZWXE1bmxWaWoyNTNCOGp6UjdGN0I5dVdaTmZzYWxtbC1LNVBjeHVQNUUzRlV5aEFybDdvYkNDN05pQnZ1d3ZaM0FBNUgxcnkxTnBOQVJF?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight sees Q2 sales of $27M as Alcon deal adds revenue", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPTHlVZGhxOHNVdkU2cFZab3B6bE1xRVZYWVdKbklMQUZVWFV6SWF6V25TNEdMNERlNXBhOEMyNTRGYy1nT3lpcEswUUNPbEZiYWEtc0piZHVqSGp1aTRObWtHQXRJemRUMlpxaDJSclBnM1RKVDFjbGlNQTBRMkVyWmZkNFVHajhsY19qUV9TTEozblBwblFmM1h4QnotRDVDYnRCc2dtZ1Q2SDlJYXJTd2FvS3FfYXpjWGJfNnliaw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight (NASDAQ: RXST) cuts 2026 sales outlook but lifts margin view", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPRzdvWWx3SnVPRU14aUJ0UmxQTEN2S2xwREhDdHlhcFJjNHFHNHlWSFRXaS1UNDRWa3o4a0ZVSEhjekR3M2t6VWlHMW93WTZTMkc4dVJlSldJWFJIaDhHblJYVjlUWWFuT3ZYYlViV3pwVGFQb0N1aGpOVzh6TXZackxxRElzMGZwNnktaG9OeUpRUDN3VW9TTENNODVHSURUNUFJ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rxsight-inc-present-stifel-2026-201000843.html", "source_name": "GlobeNewswire", "published_at": "2026-05-19T20:10:00+00:00", "published_display": "19 May 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight Q1 Earnings Call Highlights", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxONzhoNFFST0l5S0xFZGFmMDR4YjJ6VDhQTnNjVkcxS2RJUUxTUjlZZGJqYV9PcnlheGVGYU9URzFua0JPa19IVmtXVDNkdDVpQUNQdC1wd2wyWTJDTG11eExRcGNDMVBrbmFlYXpqMXlQSXRab2JVR0IzTU9sRzRHNzdzQzM0UlRIVkctR3MwZkYtREtIeU96SGE4SDJ5ZEgyeEFQVGp5OA?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxObXd3RVVzUHNTYUtibnhTZXRCQ1g3WEVGd2ducVhmYURZLVN0OTd1TEpPV2c2VGJHRG9TZU5NaXhNbjJDZTdnUDZqSzJ4TVoyRXJIYkwwT1V3c2FUdHdjbWxwZzNIazFmR25XSzFJcThqaFdia3RycUZfMW54WVR2TTVSSlpNVXVRdFJ6blZGV0VHZ0lIcHk1QUZhTDlqakV0dHI3N1JQeXFCVUR6X01Zek5weFo3dl9rRjRsRGJBbURJVnJFeWtGVE5BSHJCOURRVWI4bldSU0ZzOHRUUk9uOGpwUW9keFA2UVI2UEp3?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The RxSight (RXST) Narrative Is Shifting After 2026 Guidance And Target Resets", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPTGY2WVJ5RE1zSUxmejBmOTlvTUQ4UlBmY3ZuSzBLcGF0akVFMEs2WllRQWV6RWFJWnVMdnl6UXlId2VJbW1INWlRRDBQa3RUb1RVZi1md1YtNmxKNUNvc0swbW5rekZvUVQ3LVZIU0FFTlBWeVFvZ1FZS25Qd0hHNU5OM1ZJeWtwNWRSMks1T0JGdmlhWU1teWk1eFdGejgwMHg4?oc=5", "source_name": "Market source", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors can watch RxSight's Bank of America fireside chat May 13", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOaXc3MHVJcExubmdmR1c1WmwtOXhmM1hGcVI2QzROUWpIdEJJWjh2aHFGY21qb3d4V1Z3b3pYa0NWb002UTh1STQtNHFqWDNUbU1ndlFwOVpoTWlod0Y5dm95QV91Y3pOVWxuTXpxcUt5aVNJLUdlQXppX0pRZmdDOHdGSWI4VlBEVTRUdHhEMGU5OUkxamxFdjlscC1EWEpibXNZcWoyQUtiZG51WGF1NUZn?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Story Is Shifting For RxSight (RXST) On Guidance Leadership And Valuation", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPZlVIX00yd3FXS2pHQUtHb1F4dDQ3Yk94ZlYyOWtYWW51ckdqMVBqVmp1bEF6a3Ytb1YzREdlQ3VKZnNpV1BBYzVERHJFS19BR0VsYWo2Z015THYwWDBDTkNDbHQ5MzlKQlpTcFBVOV9KWU42YXhDTHEwWnhkTmk0VHFndVhpczFsYXNWNlNFaXM0N01JaElhWnUxRXcwRjVIVXNn?oc=5", "source_name": "Market source", "published_at": "2026-04-04T07:00:00+00:00", "published_display": "04 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight, Inc. Common Stock (RXST) Stock Price Today: $5.25", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTFBOYnBmNE1CQzFhRmdpNFZYMGN0T3dQWDB0a3VBMm1uNFhmLS04c25OcHotc2x5N1N2cllPa0FIUkhMRzZSN3BTbHJiN2hwN0tPYUVYejBxZw?oc=5", "source_name": "Gotrade", "published_at": "2026-01-13T02:40:24+00:00", "published_display": "13 Jan 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Hopeful That RxSight (NASDAQ:RXST) Will Use Its Cash Wisely", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-10T08:00:00+00:00", "published_display": "10 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight, Inc. Reports Third Quarter 2024 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOOFlkRTlwY3lDX3lyUmVKc2lwaks4aEdvN0lqVnl6d2gtSVJpa3JwX2JpYUMtbjFmREtoZERZOWdfZW5oRGgxV25KOEM3RjNZTlVab2JoRWJ5NS1GNFpIQVRZLWhlUVNmOHJyY0d4SjF3WUdHSW9lMzZjU0tXTGx3RzdEZm1zSzI1ZHZuNDVBZERXQk9FcDl5TWFHQ2N0czZBTzdZMVBlRzBBcXBrNTMxWXF5N2JZc1VTRDJQQXFDV0lSY1kxUVE?oc=5", "source_name": "GlobeNewswire", "published_at": "2024-11-07T08:00:00+00:00", "published_display": "07 Nov 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RxSight (RXST) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE9uaTA0bTRkbVU5dGNmTUltMlNkZE9jZlBGMFVfRmYzMkpmbHJxb0xsZjE3aXJYOGlmUDdBdzh4X0pnRFRIeW8zTGh3S29jWGpCeFlibG9LcHBnQkFkQm9kMm9VWUVyUQ?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T14:53:49+00:00", "published_display": "11 May 2024 14:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Reflecting On Medical Devices & Supplies - Specialty Stocks\u2019 Q1 Earnings: Integer Holdings (NYSE:ITGR)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNUFd1SUpRcWlCdEFjU1YzNTZkdjBfRkwyY2lBYjh1ZXZlZTlyVlpWSWx1bExvckFrNHNhUEdVTGNFWUxaMkVDZUV2c2hPS1h2YVhNSHNsVzFYNUFrNHBnRVM1STRsa2Zmb0VXeEQ4UFRGNDBOWXZfWVU5VFUyQ3JZZm9KamZMWXVDSEtNMWwyVktpaEZfRjVNU1BYaWJ3NnpNUmRyMEpsSzBXdw?oc=5", "source_name": "Market source", "published_at": "2026-07-14T18:07:11+00:00", "published_display": "14 Jul 2026 18:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks Q1 Earnings: ICU Medical (NASDAQ:ICUI) Firing on All Cylinders", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNTWR3bzJReVB0UTNleWx6WDlmRW1rYmpLdkptZHdadzVERk1hTzdEV0M1Z2tuRUx2cldOT2d3WlVDank5Y01EWWFfWXdWNkJFdkNFcnhjMjdCQ1Y2aFBVbndiNXVBY0F5dDRpU2Fla25fVWRTUlNROXFwYXNXT2czUm5Nbl9QUFhFTEhHd1ZKTzJUSzhJWjN6QnNNUEVBTVEyR0l6YkZacUVsdw?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q1 Earnings Outperformers: Artivion (NYSE:AORT) And The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQWlEweko5d2hyZUFhUjRsYU1QcElacmR0UktDcFZGUmFXSHpGN05OLV9tYS1VRTlfTHpGRXEzNi12cXZlcTJYVDhZRTZnWG1DUEVFT3hxMG5RcUpORUsyQWN3VVY0eENoZnFMYkdLOXk1Y2d5SFluWDBZU2ZsUl90cHZWY2pKQXZwS212WkcxejJjQ3hlYmtqMFRhWm1neHVYRDZvUzFtVmM4dXVY?oc=5", "source_name": "Market source", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Diversified Stocks Q1 Results: Benchmarking Stryker (NYSE:SYK)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNb1NaVXV6UW42emtDUzh5ckhKVjc2X29fSlFRRDVIVnRLWXpoWEYxUnVKNGZuLVN6ZWhxVno1SGluMEdLcmNrOGN1ZjlsWFpVRWxYbW9aYy01VFFpVzlncWtBYzF3YkJfNzhwTi1BcWlpVF9pUTU4QnNGWkJSV3YwRXVCUzk2Z2NUMWFjVkJOV2hSbFRrRnIxSWxNUGRoQmhQeDVBRjhYSnhvMDJqUThjYjBHRjhTRTBDdDZJd1k3LU5DTjU2cUx6TXFNdHhVS1FfdlFmaWZLNk41cFk?oc=5", "source_name": "StockStory", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Medical Devices & Supplies - Specialty Q4 Earnings: Globus Medical (NYSE:GMED) is the Best in the Biz", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcDFMNmtOVk5PVFM1YzMyVWhyS3dwY0dMVE5BUng5U1JoOFRQMXNFRGxTMmlBRUV0bENRSWFXTDFZOXBQQkNZT0FOWDdISjRCcU9pRV9aNHBwUVBuZkVEV3g1dklVY19KOE9iWUNpNUtMS2NuOEcxMlQtNU8ydURybEdkNVoxZThWLTBIeVhid2NjQ0FWWTUzb2dxcmlMQThFQmZ4bldzRjcwUQ?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks\u2019 Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOdkl6Ym5HSGVhZUw3TzNlNVFPSjdDQk5NMTVSRW1xVnh3RE5RNU9veVR0TDEtcVdxV3BYelI0bWxCYXgwWmhZQ3ZONUVRdlhjX0ZiMklRVDJQRXN0LXcyVWVnb0E2WTdiRERtZk1pNGpmVHhWbHl5eHJuNnBtTDVPMUluTmRsQUVqYjNlSl8zR3djclh0X2ZIc1gzTlhPanR6ZTJ6R1FB?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPaTgxS3dlMlZ5dDZ3dFlGdG9yRWFubkVqMk9yOTN6OEtyemljTWJGYUcxb2pmd2FTNTFKMlhIVGxrdlJsOG5iY1VQaXE4ZmYycTVpRkE0aEJ3QlB5bC10ZXN2dTFYNy0wRWdrNURVUlo5dEMzQklxQ0kwQTRkOXE0UDdTMkRGRWxoQ1ZQeG4tOXNONlR2SkxfZW5ST1B6N3BBeFZZQ3N1UFE?oc=5", "source_name": "Market source", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: CooperCompanies (NASDAQ:COO) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxOellVLTAtRXF1dTFacmVLUmptUVpDSkxGX0MtY2hCY2l3ajU4M25SMG95OHdlc1RHN1dmaHZZMF9uQ0o3R1FBa0NzQUtZMjIzMjU1bmttbGZsZUplQkd5Vmd2NEJoQ0NnbVhmVXppdWhiQkdpcGpQVFJVSHRBXy1pbnFJbXI0R2w3MmlvMEdCY2dGYVE4cWY2MENmeEp1ME9mZEFqSDVtdThTMk9kbUhIdXMtR0k?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Integer Holdings (NYSE:ITGR) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxQZXhDWktWZlhhSHlxNVZrNWllaDhhWlNXZmhKYlQ4ODRJMHozNTR2TVVKSWVrQV94bzNNU0hfVW5qODRlWW01anFmTG5SYmZoUlJpU09UbkpSemxVbHRGb1F1MGVvZFdqSEVBcUZ5Ti1ZVHlzY3pZYTdCS21RcDJPTnppdWRKVlZjd2ZUeA?oc=5", "source_name": "Market source", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPeVpVN2I3X3lJNXd3TXJmRWV4X0RvRDdYR3l5a1k1SjMxUlhsWHdrUUNuZ1JIaUg4czdhZlA2VDVIallROFFuNmZXcnNzS1d3Vm0wS0tLMmlFVWdkUThsRDZYdTdZV3k3WkRjaUZSMUQ3dkRKYm5ZOVBjMVVBdTRjYQ?oc=5", "source_name": "Market source", "published_at": "2026-03-12T07:00:00+00:00", "published_display": "12 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q4 Earnings: Enovis (NYSE:ENOV) In The Context Of Other Medical Devices & Supplies - Specialty Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNMzBPcXU1cnZKekZnaGlNVk05ZWFTWThNOS0tTlpvQjdaLVZIWlVXUk50NnVoQ0pPWWJpZUpWcVJyVDJMd2RJREVDbEEzTlU5UGhBbWtxWVEyVkdaMTVuNXZpaWFMNTZUQ2d0OW9Rc29kalJRY21naWlHZDBLS3RuZV9wdTdIUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 97, "total_relevant": 63, "sentiment_summary": {"positive": 17, "negative": 9, "neutral": 37, "score": 53, "total": 63, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 75, "events": [{"event": "general", "label": "Market update", "weight": 14.45, "count": 25}, {"event": "earnings", "label": "Earnings", "weight": 8.94, "count": 19}, {"event": "deals", "label": "Deals and strategy", "weight": 3.65, "count": 6}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.2, "count": 4}, {"event": "guidance", "label": "Guidance", "weight": 2.2, "count": 4}], "positive_events": 17, "negative_events": 9}, "market_context": {"has_market_context": true, "latest_close": 5.55, "latest_week": "2026-07-17", "one_week_move": 12.1, "four_week_move": 17.3, "twelve_week_move": -23.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.517375, "market_dynamics_buy_signal": false, "relative_strength": -38.954091, "fair_value_gap": -80.1, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 46.9379, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+12.1% over one week, +17.3% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 60, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 18}, {"label": "Stock Titan", "count": 8}, {"label": "GlobeNewswire", "count": 6}, {"label": "Investing.com", "count": 4}, {"label": "Moomoo", "count": 2}, {"label": "Simply Wall Street", "count": 2}, {"label": "VisionMonday.com", "count": 2}, {"label": "MT Newswires", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 52}, {"label": "Industry context", "count": 11}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 25}, {"label": "Earnings", "count": 19}, {"label": "Deals and strategy", "count": 6}, {"label": "Analyst action", "count": 4}, {"label": "Regulatory and legal", "count": 4}, {"label": "Guidance", "count": 4}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "52", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+12.1% over one week, +17.3% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "BlackRock Portfolio Management (RXST) discloses 7.2% beneficial stake in RxSight"}], "updated_at": "2026-07-21T20:43:44.945979+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}